Understanding this terminology is crucial because it forms the standardized language used by healthcare professionals, regulators, and pharmaceutical companies worldwide to communicate about drug safety.
1. Adverse Event (AE) / Adverse Experience
- Definition: Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product, which does not necessarily have a causal relationship with this treatment.
- Simple Explanation: Something bad that happens to a patient while they are taking a drug, whether the drug caused it or not (e.g., a patient taking a new antibiotic gets into a car accident—the accident is an AE).
- Key Point: It’s a broad term that captures all negative medical events.
2. Adverse Drug Reaction (ADR)
- Definition: A response to a medicinal product which is noxious and unintended, and for which a causal relationship with the medicinal product is at least a reasonable possibility.
- Simple Explanation: A harmful side effect that is believed to be caused by the drug.
- Key Point: All ADRs are AEs, but not all AEs are ADRs. The key difference is the suspected causal link.
3. Serious Adverse Event (SAE) / Serious Adverse Drug Reaction (Serious ADR)
An event is considered “Serious” if it meets one or more of the following criteria:
- Results in death.
- Is life-threatening (the patient was at immediate risk of death from the event).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Results in persistent or significant disability/incapacity.
- Is a congenital anomaly/birth defect.
- Is a medically important event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other outcomes.
- Key Point: “Serious” is a regulatory definition based on the outcome, not the severity of the event. A severe migraine is not “serious” by this definition unless it leads to hospitalization.
4. Unexpected Adverse Drug Reaction
- Definition: An ADR whose nature, severity, or outcome is not consistent with the information in the product’s reference safety information (e.g., the Company Core Safety Information (CCSI) or the local Summary of Product Characteristics (SmPC) for healthcare professionals).
- Simple Explanation: A side effect that is not listed in the drug’s official description or is listed but occurs in a much more severe form.
- Key Point: “Unexpected” drives expedited (fast) reporting to regulators.
5. Causality Assessment
- Definition: The systematic evaluation of the likelihood that a drug caused a reported adverse event. It is a judgment about the strength of the relationship.
- Common Categories:
- Certain: A clear, undeniable link.
- Probable/Likely: The evidence strongly suggests a link.
- Possible: The evidence is consistent with a link, but other factors could have caused it.
- Unlikely: The evidence does not support a link.
- Conditional/Unclassified: More data is needed.
- Key Point: This is a critical medical and scientific judgment, not just a box to tick.
6. Signal
- Definition: Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, that is judged to be of sufficient likelihood to justify verificatory action.
- Simple Explanation: A “hunch” or “hypothesis” that a drug might be causing a specific side effect, based on a careful review of individual reports or data analysis.
- Example: If 5 separate ICSRs are received all describing liver failure in patients taking “Drug X,” this cluster forms a potential signal of drug-induced hepatotoxicity that must be investigated.
7. Validated Signal
- Definition: A signal that has been verified through a rigorous process of evaluation and is confirmed to represent a potentially causal association that requires further analysis or regulatory action.
- Key Point: Not all signals are true; validation separates the real concerns from false alarms.
8. Individual Case Safety Report (ICSR)
- Definition: The format and content for reporting one or more suspected adverse reactions in a single patient at a specific point of time. It is the fundamental unit of pharmacovigilance data.
- Key Point: This is the document that captures all the details of a single suspected side effect. A valid ICSR requires four elements: Identifiable Patient, Identifiable Reporter, Suspect Drug, and Adverse Event.
9. MedDRA (Medical Dictionary for Regulatory Activities)
- Definition: A highly specific standardized medical terminology used to classify adverse event information. It is the international “language” for coding safety data.
- Simple Explanation: When a doctor reports a “heart attack,” it is coded in the database as “Myocardial Infarction.” When a patient reports a “stomach ache,” it might be coded as “Abdominal pain upper.”
- Key Point: MedDRA ensures consistency. Without it, searching for “heart attack,” “MI,” and “myocardial infarction” would yield different results.
10. Expedited Report
- Definition: A rapid, individual notification to regulatory authorities about a specific, serious case. It is required for serious and unexpected ADRs.
- Timeline: Typically within 15 calendar days for most serious, unexpected cases (and even 7 days for fatal/life-threatening cases in some regions).
- Key Point: This is the “emergency alert” system for drug safety.
11. Periodic Safety Update Report (PSUR)
- Definition: A report providing a comprehensive, periodic analysis of the worldwide safety data of a marketed drug. It presents a cumulative review of the drug’s risk-benefit balance at defined time points after its authorization.
- Key Point: This is the “big picture” report that looks at all the accumulated safety data over time, not just individual cases.
12. Risk Management Plan (RMP)
- Definition: A detailed document describing the risk management system for a specific medicinal product. It includes plans for proactively identifying, characterizing, preventing, or minimizing a product’s risks.
- Key Point: It’s a proactive “safety plan” for a drug, especially for new products with unknown long-term risks.
13.Post-Authorization Safety Study (PASS)
- Definition: A study conducted after a drug has been marketed to gather additional safety information, often in a real-world setting. It can be either voluntary or required by a regulatory authority.
- Key Point: These studies are part of a proactive Risk Management Plan (RMP).
14. Post-Marketing Surveillance (PMS)
- Definition: The process of monitoring the safety of a drug after it has been released on the market. Also known as Phase IV of drug development.
- Key Point: This is where pharmacovigilance truly happens, as the drug is used by a much larger and more diverse population than in clinical trials.
15. Benefit-Risk Balance
- Definition: The central evaluation in pharmacovigilance. It is an assessment of whether the therapeutic benefits of a medicine outweigh its risks for a given population or individual patient.
- Key Point: The ultimate goal of PV is not to make drugs 100% risk-free (which is impossible) but to ensure their benefits consistently outweigh their risks.
16. Company Core Safety Information (CCSI)
- Definition: All the relevant safety information contained in the company’s Reference Safety Information for a drug, which is the basis for determining whether an ADR is “expected” or “unexpected.”
- Key Point: This is the company’s master list of known ADRs for a drug.
17. Company Core Data Sheet (CCDS)
- Definition: A document prepared by the marketing authorization holder that contains all the relevant safety information for a drug, including its indications, dosing, contraindications, and adverse reactions.
- Key Point: The CCSD is the company’s global reference for determining if an ADR is “expected” or “unexpected.”
18. Suspected Unexpected Serious Adverse Reaction (SUSAR)
- Definition: An adverse reaction that is Serious, Unexpected, and there is a suspected causal relationship to the investigational drug in a clinical trial.
- Key Point: SUSARs are subject to the most rapid (expedited) reporting requirements during clinical development.
19. ICH E2B
- Definition: The specific International Council for Harmonisation (ICH) guideline that provides the international standard for the electronic transmission of ICSR data.
- Key Point: When people say “E2B,” they are referring to this standardized format for sending safety reports.
20. Black Triangle Drug (▼)
- Definition: A symbol used in the European Union and the UK next to the name of a medicine to indicate that it is subject to additional monitoring. This typically includes all new active substances, biological medicines, and products with significant new safety information.
- Key Point: It encourages healthcare professionals and patients to be extra vigilant and report any suspected ADRs for these products.
